Puma Biotechnology, Inc. (PBYI) SEC Filing 8-K Material Event for the period ending Friday, June 28, 2019

Puma Biotechnology, Inc.

CIK: 1611613 Ticker: PBYI

View differences made from one to another to evaluate Puma Biotechnology, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Puma Biotechnology, Inc..


Assess how Puma Biotechnology, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Puma Biotechnology, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: PBYI
CIK: 1401667
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-189281
Submitted to the SEC: Wed Jul 03 2019 4:58:03 PM EST
Accepted by the SEC: Wed Jul 03 2019
Period: Friday, June 28, 2019
Industry: Pharmaceutical Preparations
  1. New Agreement
  2. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: